Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ARXIS INC (ARXS)
NASDAQIndustrialsAerospace & DefenseSnapshot 2026-11-05
$48.52-3.96%
Close 2026-11-05 · 1-day change
NASDAQIndustrialsAerospace & DefenseSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.94 → 1.00 EPS · FY ending Dec 31, 2027 · 5 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 4 to 5; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ARXS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Expand product portfolio via strategic acquisitions | A supporting condition in ARXIS INC's published investment case. The stated target is Complete acquisitions that expand key segments. | Intact | No meaningful acquisitions completed or integration fails | 3 acquisitions completed vs 0 required News confirms completion of Omnetics, MagCanica, and a $770M connector acquisition, reinforcing the roll-up strategy. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ARXS is a growth business combining organic expansion with acquisitions, rather than a turnaround story. Its long-term thesis is intact: recent results show strong growth and earnings quality, while management’s acquisition execution is mixed.
The valuation is expensive versus peers, and the expectations gap is positive, with some additional value tied to potential future opportunities. Valuation rose sharply in the recent period while company momentum fell, so the setup is stretched even though the evidence does not show a broader pattern of weak fundamentals and high fragility.
Near term, recent execution is strong: Q3 revenue grew 36% year over year, organic growth was 29%, and adjusted EBITDA margin improved to 45.4%. The main risk is a guidance cut after the recent increase, which could hurt management credibility; the near-term miss risk is described as low, but past misses and smaller company size remain relevant.
Over the next 1 to 3 years, the thesis depends on sustaining organic growth and margin gains while integrating acquisitions through a disciplined, repeatable strategy. Sector conditions also matter: continued strength from industrial bellwethers could support the sector backdrop, while weaker results or guidance could remove that tailwind.
The multi-year view remains intact on strong recent fundamentals, but the expensive valuation and cooler company momentum leave less room for execution to weaken. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in ARXIS INC's published investment case. The stated target is $720M+. |
| Intact |
| EBITDA falls below $720M in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve full-year 2026 revenue of $1.86B to $1.88B | A primary condition in ARXIS INC's published investment case. The stated target is ~$1.87B. | Intact | Revenue falls below $1.86B in 2026 | Revenue: $563.979M FY2026-Q3; GAAP. Published target: ~$1.87B. Target period is not explicitly aligned with this observation. Oct 29, 2026563,979,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.71 → $1.00 · observed estimates
$2.08B → $2.44B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.71 | $2,076,978,568 | 5 / 7 |
| 2026-07-25 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-07-26 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-07-27 | $0.71 | $2,076,978,570 | 5 / 7 |
| 2026-07-28 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-07-29 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-07-30 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-07-31 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-08-01 | $0.93 | $2,078,163,380 | 8 / 10 |
| 2026-08-02 | $1.15 | $2,168,733,100 | 8 / 10 |
| 2026-08-03 | $1.15 | $2,168,733,100 | 8 / 10 |
| 2026-08-04 | $1.15 | $2,168,733,100 | 8 / 10 |
| 2026-08-05 | $1.21 | $2,224,799,090 | 9 / 11 |
| 2026-08-06 | $1.21 | $2,224,799,090 | 9 / 11 |
| 2026-08-07 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-08 | $1.22 | $2,224,790,530 | 10 / 11 |
| 2026-08-09 | $1.22 | $2,224,790,530 | 10 / 11 |
| 2026-08-10 | $1.22 | $2,224,790,530 | 10 / 11 |
| 2026-08-11 | $1.22 | $2,224,790,530 | 10 / 11 |
| 2026-08-12 | $1.22 | $2,224,790,530 | 10 / 11 |
| 2026-08-13 | $1.22 | $2,224,790,530 | 10 / 11 |
| 2026-08-14 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-15 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-16 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-17 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-18 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-19 | $0.78 | $2,140,773,349 | 5 / 7 |
| 2026-08-20 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-21 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-22 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-23 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-24 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-25 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-26 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-27 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-28 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-29 | $0.87 | $2,252,244,466 | 6 / 8 |
| 2026-08-30 | $0.87 | $2,248,516,757 | 6 / 8 |
| 2026-08-31 | $0.87 | $2,248,516,757 | 6 / 8 |
| 2026-09-01 | $0.87 | $2,248,516,757 | 6 / 8 |
| 2026-09-02 | $0.87 | $2,248,516,757 | 5 / 7 |
| 2026-09-03 | $0.87 | $2,248,516,757 | 5 / 7 |
| 2026-09-04 | $0.87 | $2,248,516,757 | 5 / 7 |
| 2026-09-05 | $0.89 | $2,248,471,739 | 5 / 7 |
| 2026-09-06 | $0.89 | $2,248,471,739 | 5 / 7 |
| 2026-09-07 | $0.89 | $2,248,471,739 | 5 / 7 |
| 2026-09-08 | $0.92 | $2,248,471,739 | 5 / 7 |
| 2026-09-09 | $0.92 | $2,248,471,739 | 5 / 7 |
| 2026-09-10 | $0.92 | $2,248,471,739 | 5 / 7 |
| 2026-09-11 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-12 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-13 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-14 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-15 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-16 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-17 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-18 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-19 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-20 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-21 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-22 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-23 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-24 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-25 | $0.92 | $2,248,471,737 | 5 / 7 |
| 2026-09-26 | $0.92 | $2,269,631,828 | 5 / 7 |
| 2026-09-27 | $0.92 | $2,269,631,828 | 5 / 7 |
| 2026-09-28 | $0.92 | $2,269,631,828 | 5 / 7 |
| 2026-09-29 | $0.92 | $2,269,631,828 | 5 / 7 |
| 2026-09-30 | $0.92 | $2,269,631,828 | 5 / 7 |
| 2026-10-01 | $0.92 | $2,287,941,965 | 5 / 7 |
| 2026-10-02 | $0.92 | $2,287,941,965 | 3 / 3 |
| 2026-10-03 | $0.94 | $2,312,314,692 | 4 / 4 |
| 2026-10-04 | $0.94 | $2,312,314,692 | 4 / 4 |
| 2026-10-05 | $0.94 | $2,312,314,692 | 4 / 4 |
| 2026-10-06 | $0.94 | $2,317,041,965 | 4 / 4 |
| 2026-10-07 | $0.94 | $2,317,041,965 | 3 / 4 |
| 2026-10-08 | $0.94 | $2,317,086,983 | 3 / 4 |
| 2026-10-09 | $0.95 | $2,347,760,060 | 4 / 5 |
| 2026-10-10 | $0.95 | $2,347,760,060 | 4 / 5 |
| 2026-10-11 | $0.95 | $2,347,760,060 | 4 / 5 |
| 2026-10-12 | $0.95 | $2,347,760,060 | 4 / 5 |
| 2026-10-13 | $0.95 | $2,372,689,333 | 4 / 6 |
| 2026-10-14 | $0.95 | $2,372,689,333 | 4 / 6 |
| 2026-10-15 | $0.95 | $2,372,689,333 | 4 / 6 |
| 2026-10-16 | $0.95 | $2,372,689,333 | 4 / 6 |
| 2026-10-17 | $0.95 | $2,372,689,333 | 4 / 6 |
| 2026-10-18 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-19 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-20 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-21 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-22 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-23 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-24 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-25 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-26 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-27 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-28 | $0.95 | $2,372,644,315 | 4 / 6 |
| 2026-10-29 | $0.95 | $2,372,648,153 | 5 / 6 |
| 2026-10-30 | $0.95 | $2,386,284,516 | 5 / 6 |
| 2026-10-31 | $1.00 | $2,434,070,963 | 6 / 6 |
| 2026-11-01 | $1.00 | $2,433,825,982 | 5 / 6 |
| 2026-11-02 | $1.00 | $2,441,456,371 | 5 / 7 |
| 2026-11-03 | $1.00 | $2,443,025,153 | 6 / 8 |
| 2026-11-04 | $1.00 | $2,443,025,153 | 5 / 7 |
| 2026-11-05 | $1.00 | $2,443,025,153 | 5 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.